Thenappan Chandrasekar1,2, Annette Erlich3,4, Alexandre R Zlotta5,6,7. 1. Department of Surgical Oncology, Division of Urology, Princess Margaret Cancer Centre, University of Toronto and University Health Network, Toronto, ON, Canada. 2. Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA. 3. Department of Surgery, Division of Urology, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada. 4. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada. 5. Department of Surgical Oncology, Division of Urology, Princess Margaret Cancer Centre, University of Toronto and University Health Network, Toronto, ON, Canada. alexandre.zlotta@sinaihealthsystem.ca. 6. Department of Surgery, Division of Urology, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada. alexandre.zlotta@sinaihealthsystem.ca. 7. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada. alexandre.zlotta@sinaihealthsystem.ca.
Abstract
PURPOSE OF REVIEW: Bladder cancer (BCa) management had remained unchanged for 20+ years with clinicians, in contrast to many other cancer types, rarely relying on molecular characteristics to guide management. The past 5 years have yielded significant advances in our knowledge of the molecular basis of BCa and concurrent advances in systemic therapy. We aim to highlight the key developments and potential future direction of BCa management. RECENT FINDINGS: Next-generation sequencing (NGS) has drastically altered the understanding of muscle-invasive BCa (MIBC) and non-muscle invasive BCa (NMIBC). MIBC molecular subtyping efforts from several groups worldwide grouped into an international consortium into five classes, broadly grouped into basal and luminal subtypes, have attempted to improve prediction of clinical outcomes and treatment response, either chemotherapy or immunotherapy. NMIBC molecular subtyping is yielding similar disease stratification, superior to histopathology alone. Additionally, with new actionable targets being identified for patients non-responsive to traditional therapy, ongoing and upcoming clinical trials are increasingly emphasizing the importance of the molecular testing. The molecular characterization of bladder cancer is rapidly progressing and will likely alter treatment paradigms in the near future.
PURPOSE OF REVIEW: Bladder cancer (BCa) management had remained unchanged for 20+ years with clinicians, in contrast to many other cancer types, rarely relying on molecular characteristics to guide management. The past 5 years have yielded significant advances in our knowledge of the molecular basis of BCa and concurrent advances in systemic therapy. We aim to highlight the key developments and potential future direction of BCa management. RECENT FINDINGS: Next-generation sequencing (NGS) has drastically altered the understanding of muscle-invasive BCa (MIBC) and non-muscle invasive BCa (NMIBC). MIBC molecular subtyping efforts from several groups worldwide grouped into an international consortium into five classes, broadly grouped into basal and luminal subtypes, have attempted to improve prediction of clinical outcomes and treatment response, either chemotherapy or immunotherapy. NMIBC molecular subtyping is yielding similar disease stratification, superior to histopathology alone. Additionally, with new actionable targets being identified for patients non-responsive to traditional therapy, ongoing and upcoming clinical trials are increasingly emphasizing the importance of the molecular testing. The molecular characterization of bladder cancer is rapidly progressing and will likely alter treatment paradigms in the near future.
Authors: Floris H Groenendijk; Jeroen de Jong; Elisabeth E Fransen van de Putte; Magali Michaut; Andreas Schlicker; Dennis Peters; Arno Velds; Marja Nieuwland; Michel M van den Heuvel; Ron M Kerkhoven; Lodewijk F Wessels; Annegien Broeks; Bas W G van Rhijn; René Bernards; Michiel S van der Heijden Journal: Eur Urol Date: 2015-01-27 Impact factor: 20.096
Authors: C Billerey; D Chopin; M H Aubriot-Lorton; D Ricol; S Gil Diez de Medina; B Van Rhijn; M P Bralet; M A Lefrere-Belda; J B Lahaye; C C Abbou; J Bonaventure; E S Zafrani; T van der Kwast; J P Thiery; F Radvanyi Journal: Am J Pathol Date: 2001-06 Impact factor: 4.307
Authors: Yu Liu; Aidan P Noon; Eduardo Aguiar Cabeza; Jess Shen; Cynthia Kuk; Christine Ilczynski; Ruoyu Ni; Balram Sukhu; Kin Chan; Nuno L Barbosa-Morais; Thomas Hermanns; Benjamin J Blencowe; Azar Azad; Theodorus H van der Kwast; James W F Catto; Alexandre R Zlotta; Jeffrey L Wrana Journal: Eur Urol Date: 2014-09-06 Impact factor: 20.096
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Seth P Lerner; David J McConkey; Katherine A Hoadley; Keith S Chan; William Y Kim; François Radvanyi; Mattias Höglund; Francisco X Real Journal: Bladder Cancer Date: 2016-01-07
Authors: Vincenzo Cuccurullo; Giuseppe Danilo Di Stasio; Francesco Manti; Pierpaolo Arcuri; Rocco Damiano; Giuseppe Lucio Cascini Journal: Diagnostics (Basel) Date: 2021-05-11